# D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer

> **NCT06622057** · PHASE3 · NOT_YET_RECRUITING · sponsor: **InnoPharmax Inc.** · enrollment: 195 (estimated)

## Conditions studied

- Biliary Tract Cancer (BTC)

## Interventions

- **DRUG:** D07001-Softgel Capsules
- **DRUG:** Placebo
- **COMBINATION_PRODUCT:** Capecitabine

## Key facts

- **NCT ID:** NCT06622057
- **Lead sponsor:** InnoPharmax Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 195 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06622057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06622057, "D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06622057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*